This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 704986
Submitted by lobbyist on: November 24, 2017 08:07:26 AM
Accepted by Registrar on: November 24, 2017 09:41:11 AM
Designated Filer Information
| Lanman, Lydia |
| 3650 Danforth Avenue | |
|
Toronto, ON, M1N 2E8
|
587-337-4043 |
| Canada |
Organization Information
| Eli Lilly Canada Inc. |
| Eli Lilly is committed to providing answers that matter in medicine, life sciences and health care. As a leading inovation-driven pharmaceutical corporation, Lilly is developing a growing portfolio of products by applying the latest research from its own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most up-to-date technological tools and by providing exceptional service to its customers. Headquartered in Indianapolis, Indiana, Lilly provides answers; through medicines and information; for some of the world's most urgent medical needs. Eli Lilly Canada, headquartered in Toronto, Ontario, employs more than 500 people across the country. Additional information about Eli Lilly Canada can be found at www.lilly.ca. |
| 3650 Danforth Avenue | |
|
Toronto, ON, M1N 2E8
|
587-337-4043 |
| Canada |
Relevant Affiliates
Government or Government Agency Funding
Other Controlling or Directing Interests
Active Registration Period
| November 24, 2017 | |
| May 24, 2018 |
Organization's In-House Lobbyists
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA)initiatives, public drug plan design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | May 8, 2018 |
| Minister | Horgan, John | Premier | May 8, 2018 |
| Minister | James, Carole | Minister of Finance | May 8, 2018 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | May 8, 2018 |
| Public Agency | Health | May 8, 2018 | |
| Public Agency | Jobs, Trade and Technology | May 8, 2018 |
Science and Technology
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | May 8, 2018 |
| Minister | Glumac, Rick | Parliamentary Secretary for Technology | May 8, 2018 |
| Minister | Horgan, John | Premier | May 8, 2018 |
| Minister | James, Carole | Minister of Finance | May 8, 2018 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | May 8, 2018 |
| Public Agency | Jobs, Trade and Technology | May 8, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA)initiatives, public drug plan design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | May 8, 2018 |
| Minister | Horgan, John | Premier | May 8, 2018 |
| Minister | James, Carole | Minister of Finance | May 8, 2018 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | May 8, 2018 |
| Public Agency | Health | May 8, 2018 | |
| Public Agency | Jobs, Trade and Technology | May 8, 2018 |
Science and Technology
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | May 8, 2018 |
| Minister | Glumac, Rick | Parliamentary Secretary for Technology | May 8, 2018 |
| Minister | Horgan, John | Premier | May 8, 2018 |
| Minister | James, Carole | Minister of Finance | May 8, 2018 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | May 8, 2018 |
| Public Agency | Jobs, Trade and Technology | May 8, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA)initiatives, public drug plan design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | November 24, 2017 |
| Minister | Horgan, John | Premier | November 24, 2017 |
| Minister | James, Carole | Minister of Finance | November 24, 2017 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | November 24, 2017 |
| Public Agency | Health | November 24, 2017 | |
| Public Agency | Jobs, Trade and Technology | December 4, 2017 |
Science and Technology
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Dix, Adrian | Minister of Health | November 24, 2017 |
| Minister | Glumac, Rick | Parliamentary Secretary for Technology | November 24, 2017 |
| Minister | Horgan, John | Premier | November 24, 2017 |
| Minister | James, Carole | Minister of Finance | November 24, 2017 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | November 24, 2017 |
| Public Agency | Jobs, Trade and Technology | December 4, 2017 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Discussions related to Eli Lilly's products in the following therapeutic areas for the purpose of maintaining and/or obtaining public reimbursement: diabetes, psoriasis, rheumatoid arthritis.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | November 24, 2017 |
Science and Technology
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation, research and development, clinical trials, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | May 8, 2018 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Discussions related to Eli Lilly's products in the following therapeutic areas for the purpose of maintaining and/or obtaining public reimbursement in BC: diabetes, depression, chronic pain, psoriasis, rheumatoid arthritis, pediatric human growth hormone deficiency, lung cancer, colorectal cancer, gastric cancer, soft tissue sarcoma, breast cancer.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Health | November 24, 2017 | |
| Public Agency | Provincial Health Services Authority | November 24, 2017 |